目的：观察肾衰宁胶囊联合碳酸钙治疗维持性血液透析（MHD） 合并高磷血症患者的临床疗效。方法：选择60 例MHD 合并高磷血症患者为研究对象，按随机数字表法分为观察组和对照组各30 例。2 组患者均接受规律血液透析治疗，对照组给予碳酸钙治疗，观察组给予肾衰宁胶囊联合碳酸钙治疗，疗程均为3 个月。比较2 组治疗前后血钙（Ca）、磷（P）、钙磷乘积（Ca×P） 及肌酐、尿素氮、血红蛋白、白蛋白、全段甲状旁腺激素（iPTH） 水平的变化。结果：治疗前，2 组血红蛋白、白蛋白、肌酐、尿素氮水平比较，差异无统计学意义（P＞0.05）。治疗后，观察组白蛋白、血红蛋白较治疗前提高，且明显高于对照组，差异均有统计学意义（P＜0.05）。治疗前，2 组血Ca、P、Ca×P 及iPTH 水平比较，差异无统计学意义（P＞0.05）。治疗后，2 组血P、Ca×P 较治疗前降低，且观察组血P、Ca×P 低于对照组，差异有统计学意义（P＜0.05）。治疗后，观察组血清iPTH 水平低于治疗前，且低于对照组，差异有统计学意义（P＜0.05）。结论：肾衰宁胶囊联合碳酸钙治疗MHD 合并高磷血症患者，可以有效降低血P 及Ca×P、iPTH 水平，改善患者营养状态及肾性贫血，且用药安全性良好。
Abstract： Objective： To observe the clinical effect of Shenshuaining capsules combined with calcium carbonate for maintenance hemodialysis(MHD) complicated with hyperphosphatemia. Methods：A total of 60 cases of patients with MHD complicated with hyperphosphatemia were selected and divided into the observation group and the control group according to the random number table method，with 30 cases in each group. Both groups were given routine hemodialysis；the control group was treated with hyperphosphatemia，and the observation group was treated with Shenshuaining capsules combined with calcium carbonate；both groups were treated for three months. Changes in blood calcium(Ca)，phosphorus(P)，calciumphosphorus product(Ca×P) as well as the levels of creatinine，urea nitrogen，hemoglobin，albumin and intact parathyroid hormone(iPTH) before and after treatment were compared between the two groups. Results： Before treatment， when compared levels of hemoglobin，albumin，creatinine and urea nitrogen between the two groups，there was no significance in the difference(P＞0.05). After treatment， blood albumin and hemoglobin in the observation group were significantly increased when compared with those before treatment and were obviously higher than those in the control group， differences being significant(P＜0.05). Before treatment，when compared levels of Ca，P，Ca×P and iPTH in blood between the two groups，there was no significance in the difference(P＞0.05). After treatment，the levels of P and Ca×P in blood in the two groups were decreased when compared with those before treatment，and the two levels in the observation group were lower than those in the control group，the difference being significant(P＜0.05). After treatment，level of iPTH in serum in the observation group was lower than that before treatment and that in the control group，the difference being significant (P＜0.05). Conclusion： The therapy of Shenshuaining capsules combined with calcium carbonate for patients with MHD complicated with hyperphosphatemia can effectively reduce levels of blood P， Ca × P and iPTH， and improve nutritional status and renal anemia with good medication safety.